Moving CAR T-cell therapy to earlier treatment lines is crucial. This approach targets cancer before it develops resistance and, more importantly, utilizes patient T-cells that are healthier and more effective, not having been damaged by extensive prior chemotherapy regimens.

In relapsed/refractory DLBCL, the timing of relapse is a critical factor in determining the next line of therapy. Patients who relapse within 12 months are preferred candidates for CAR-T therapy. Those relapsing after 12 months may first undergo salvage chemotherapy followed by an autologous stem cell transplant if they respond.

For third-line follicular lymphoma, where both CAR-T and bispecifics are approved, experts are leaning towards CAR-T. The long-term follow-up data for CAR-T suggests a potential for cure, making it a more compelling option for eligible patients despite logistical challenges.

An exploratory strategy for DLBCL patients involves using ctDNA to detect minimal residual disease after CAR T-cell therapy. This allows for early intervention with bispecific antibodies when the disease burden is low, potentially preventing full clinical progression, a shift from reactive to proactive treatment.

Clinical trials for second-line DLBCL used a 12-month relapse cutoff for eligibility, but this shouldn't be interpreted rigidly in practice. A patient relapsing at 13 months is biologically similar to one at 11 months and should still be strongly considered for CAR T-cell therapy over salvage chemotherapy and transplant.

As CAR-T cell therapies are increasingly adopted for second-line treatment of large cell lymphoma, epcoritamab is solidifying its role as a critical, potentially curative replacement option in the third-line setting. This establishes a clear sequential treatment pathway for patients who continue to relapse.

The TRANSFORM study quantifies the critical importance of therapy timing. DLBCL patients receiving Liso-cel CAR-T as a second-line treatment had a 95% two-year overall survival, which dropped significantly to 78% for patients who received it third-line after crossover from the standard-of-care arm.

Contrary to typical findings where real-world data underperforms, liso-cel CAR T-cell therapy in CLL demonstrates significantly better outcomes in practice than in its approval trial (over 80% response rate vs. under 50%). This suggests that using the therapy earlier in healthier, less-refractory patients unlocks its true potential.

The next major shift for CAR T-cell therapy is its integration into frontline treatment. Instead of being reserved for relapse, it's being tested as a consolidation therapy that could replace the standard two to three years of maintenance chemotherapy, dramatically shortening treatment duration.